Activation of the TP53 pathway is a therapeutic vulnerability in NUP98::KDM5A+ pediatric AML

We are happy to share that Luca has just successfully defended his PhD! As the defense was taking place in Halle the leukemia-research team made their way to Halle to support Luca on this very important day. His elaborate work focused on the fetal specific effects of the NUP98::KDM5A fusion and its effects on the vulnerability to the TP53 pathway. He performed functional genomic and proteomic analysis to explore this vulnerability and to identify a selection of synergistic drug applications. His work combines basic and translational research contributing to offering novel therapeutic options for pediatric AML.

Find Lucas work at:

Cifarelli, L.N., Activation of the TP53 pathway is a therapeutic vulnerability in NUP98::KDM5A+ pediatric AML. bioRxiv. 2025; doi: https://doi.org/10.1101/2025.09.11.675580